Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (451-460 of 869) with videos related to

Pageof 87
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma modelPaola Neri, Shaji Kumar, Maria Teresa Fulciniti, et al.
Blood|October 25, 2008
SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERKYutaka Okawa, Teru Hideshima, Paul Steed, et al.
Blood|December 14, 2002
Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arraysDharminder Chauhan, Guilan Li, Daniel Auclair, et al.
Blood|July 2, 2002
Absence of biologically important Kaposi sarcoma-associated herpesvirus gene products and virus-specific cellular immune responses in multiple myelomaChristian Brander, Noopur Raje, Paula G O'Connor, et al.
Cancer Research|July 5, 2005
Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myelomaYu-Tzu Tai, Xianfeng Li, Xia Tong, et al.
Blood Cancer Journal|August 16, 2022
γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiationHailin Chen, Tengteng Yu, Liang Lin, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 25, 2007
Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myelomaKumar Sukhdeo, Mala Mani, Yunyu Zhang, et al.
Blood|August 21, 2004
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myelomaNoopur Raje, Shaji Kumar, Teru Hideshima, et al.
British Journal of Haematology|September 17, 2013
Identification of human leucocyte antigen (HLA)-A*0201-restricted cytotoxic T lymphocyte epitopes derived from HLA-DOβ as a novel target for multiple myelomaYoon Joong Kang, Wanyong Zeng, Weihua Song, et al.
Oncogene|February 22, 2002
Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arraysDharminder Chauhan, Daniel Auclair, Elisabeth K Robinson, et al.
Pageof 87

Showing results (451-460 of 869) with videos related to

Sort By:
Pageof 87
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma modelPaola Neri, Shaji Kumar, Maria Teresa Fulciniti, et al.
Blood|October 25, 2008
SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERKYutaka Okawa, Teru Hideshima, Paul Steed, et al.
Blood|December 14, 2002
Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arraysDharminder Chauhan, Guilan Li, Daniel Auclair, et al.
Blood|July 2, 2002
Absence of biologically important Kaposi sarcoma-associated herpesvirus gene products and virus-specific cellular immune responses in multiple myelomaChristian Brander, Noopur Raje, Paula G O'Connor, et al.
Cancer Research|July 5, 2005
Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myelomaYu-Tzu Tai, Xianfeng Li, Xia Tong, et al.
Blood Cancer Journal|August 16, 2022
γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiationHailin Chen, Tengteng Yu, Liang Lin, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 25, 2007
Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myelomaKumar Sukhdeo, Mala Mani, Yunyu Zhang, et al.
Blood|August 21, 2004
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myelomaNoopur Raje, Shaji Kumar, Teru Hideshima, et al.
British Journal of Haematology|September 17, 2013
Identification of human leucocyte antigen (HLA)-A*0201-restricted cytotoxic T lymphocyte epitopes derived from HLA-DOβ as a novel target for multiple myelomaYoon Joong Kang, Wanyong Zeng, Weihua Song, et al.
Oncogene|February 22, 2002
Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arraysDharminder Chauhan, Daniel Auclair, Elisabeth K Robinson, et al.
Pageof 87